<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    Why did KZR miss earnings forecasts in Q3?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        4/11/2025 04:43pm
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">Kezar Life Sciences Inc. (KZR) did not miss earnings forecasts in Q3; in fact, the company's Q3 2024 earnings per share (EPS) estimates were actually increased by William Blair analyst M. Phipps, from ($0.34) to ($0.30). However, the company's financial results for Q3 2024 showed a reported EPS of ($0.30), which met the revised estimates set by William Blair. Therefore, Kezar Life Sciences did not miss the earnings forecasts in Q3 2024.</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am,an){return {layout:"default",data:[{noData:c,currentQuestion:d,textDescription:E,comeFrom:"AInvestShareLink",events:[],answerSource:l}],fetch:{},error:m,state:{sharePreviewModule:{loadJgySuccess:i,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:1,agent_id:a,output_media_info:[],task_id:a,language:a,source:l,cache_builder:a,reply_action:"Answer",execute_mode:v,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"Why did KZR miss earnings forecasts in Q3?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"Why did KZR miss earnings forecasts in Q3?\",\"user_id\":\"dp56322314\",\"user_name\":\"\",\"trace_id\":\"a5d0551a-ec43-404e-b317-c6fb5d4d7da1\",\"session_id\":\"a5d0551a-ec43-404e-b317-c6fb5d4d7da1\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"search",raw_data:{number:F,title:G,summary:H,full_summary:"Get Kezar Life Sciences alerts: Kezar Life Sciences, Inc. (NASDAQ:KZR – Free Report) – Investment analysts at William Blair boosted their Q3 2024 earnings per share (EPS) estimates for shares of Kezar Life Sciences in a research report issued on Tuesday, August 13th. William Blair analyst M. Phipps now anticipates that the company will post earnings of ($0.30) per share for the quarter, up from their prior forecast of ($0.34). The consensus estimate for Kezar Life Sciences’ current full-year earnings is ($1.24) per share. William Blair also issued estimates for Kezar Life Sciences’ Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($1.25) EPS, Q1 2025 earnings at ($0.35) EPS, Q2 2025 earnings at ($0.35) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.42) EPS, FY2026 earnings at ($1.53) EPS and FY2027 earnings at ($1.65) EPS. Separately, HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Kezar Life Sciences in a report on Wednesday. View Our Latest Stock Analysis on Kezar Life Sciences Kezar Life Sciences Stock Down 1.8 % NASDAQ KZR opened at $0.61 on Friday. Kezar Life Sciences has a 1 year low of $0.54 and a 1 year high of $1.69. The stock has a market capitalization of $44.66 million, a PE ratio of -0.44 and a beta of 0.28. The company has a debt-to-equity ratio of 0.05, a current ratio of 11.48 and a quick ratio of 11.49. The business’s 50-day moving average is $0.63 and its 200 day moving average is $0.77. Institutional Trading of Kezar Life Sciences Several institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC lifted its position in Kezar Life Sciences by 33.8% in the 4th quarter. SG Americas Securities LLC now owns 43,950 shares of the company’s stock valued at $42,000 after acquiring an additional 11,109 shares in the last quarter. Panagora Asset Management Inc. bought a new position in shares of Kezar Life Sciences during the f",url:I,image_url:a,video_url:a,publish_time:J,search_extra_info:{search_burial_info:{id:K,uid:w,ab:{scene_id:L,layer_exp:[{layer_id:M,exp_id:N}]}}},simhash:"e16906c2f615ce9a",msg_id:w}}],answer_chain_name:O,agent_mode:P,native_answer:a,come_from:a,text_answer:E,trace_id:e,cost:19669,event_names:a,question:d,fallback_type:Q,input_type:R,fall_back_reason:{fall_back_type:Q,risk_detail:{matched_words:[]}},session_id:e,first_return_cost:4457,cache_type:a,question_id:e,transfer_question:d,signal_type:"ON_COMPLETE",start_time:S,remote_svc:l,slots:[],answer_type:v,user_id:r,skill_name:x},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:e,session_id:e,user_id:r,question:d,source:l,raw_question:d,version:"3.4.1",action_name:x,nlu:{entity:[{type:T,value:"KZR.O",market:U}]},deep_research:c,deep_thinking:c,agent_mode:P},extra:{}},{answer_path:f,section:{id:g,info_texts:["Thinking"],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:f,section:{id:g,info_texts:["Querying Stock: KZR Total Revenue, Revenue Surprise in 2025 Q3"],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b,status:s},logs:[],extra:{action:"Querying Stock",action_input:"KZR Total Revenue, Revenue Surprise in 2025 Q3",thought:t}},{answer_path:f,section:{id:g,info_texts:["Searching Web: Kezar Life Sciences 2025 Q3 Earnings Report"],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b,status:s},logs:[],extra:{action:y,action_input:"Kezar Life Sciences 2025 Q3 Earnings Report",thought:t}},{answer_path:f,section:{id:g,info_texts:["Searching Web: Kezar Life Sciences Analyst Consensus Rating, Analyst Target Price"],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b,status:s},logs:[],extra:{action:y,action_input:"Kezar Life Sciences Analyst Consensus Rating, Analyst Target Price",thought:t}},{answer_path:f,section:{id:g,info_texts:["Searching Web: Why did Kezar Life Sciences Miss 2025 Q3 Earnings"],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b,status:s},logs:[],extra:{action:y,action_input:"Why did Kezar Life Sciences Miss 2025 Q3 Earnings",thought:t}},{answer_path:j,section:{id:V,info_texts:[],show_type:z,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:j,section:{id:V,info_texts:[],show_type:z,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:g,info_texts:["Generating Answer"],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:j,section:{id:A,info_texts:[],show_type:B,voice_txt:"Ke",text_answer:W,rich_text:W,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:j,section:{id:2000,info_texts:[],show_type:B,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:I,image_url:a,video_url:a,title:G,summary:H,index:F,publish_time:J,search_id:K,search_uid:w,search_ab:{scene_id:L,layer_exp:[{layer_id:M,exp_id:N}]},jump_type:"normal"}],is_last:b},logs:[],extra:{}},{answer_path:j,section:{id:A,info_texts:[],show_type:B,voice_txt:". However",text_answer:X,rich_text:X,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:j,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:"KZR",market_id:U,name:Y,domain:T},pos:i,section_id:A,txt:Y,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:g,info_texts:["Completed"],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:"result_page",choice:[{display_text:n,query_text:n,trace_info:{item_id:"a35b69aada09e4776807e093159a2380",item_type:k,item_name:n,rec_info:Z}},{display_text:o,query_text:o,trace_info:{item_id:"59c34657ae695a0fa7de1a68f901c973",item_type:k,item_name:o,rec_info:_}},{display_text:p,query_text:p,trace_info:{item_id:"f4d6862cdd745ed46bc82151d98110bf",item_type:k,item_name:p,rec_info:$}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:"title1",data:{h1:a,h2:a},config:{display:c,txt_style:i,type:"1",display2:c,url:a}},request_config:[{source_type:aa,related_name:ab}],puuid:C,tag:a,category:"custom",uuid:ac}],global:{urp_static_data:[{name:ab,value:{status_code:i,columns:[{type:q,index_name:ad,key:ad},{type:q,index_name:ae,key:ae},{type:q,index_name:af,key:af},{type:q,index_name:ag,key:ag},{type:q,index_name:ah,key:ah}],datas:[{send_text:n,item_type:k,rec_info:Z,display_text:n,rec_reason:a},{send_text:o,item_type:k,rec_info:_,display_text:o,rec_reason:a},{send_text:p,item_type:k,rec_info:$,display_text:p,rec_reason:a}],dataSize:aa,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:ai,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:u,"min-height":"100%",position:aj,height:u},isMaterial:c,id:ai,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:i,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:D,componentUuid:ac,script:[{name:ak,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:D,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:D},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:u,position:aj,height:u},isMaterial:b,_id:19,id:ak,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:al,voice_txt:a,tracking_info:{},uuid:C},order:{is_auto:c,render_for:al,chart_type:"command",puuid:C}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1005,info_texts:[],show_type:z,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:x,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:v,answer_chain_name:O},is_deep_research:c,deep_thinking:c,create_time:1744361056945},is_last:b}],questionItem:{data:{qStr:d,encodeFlag:c,imageData:m,docsData:[],quoteData:m},tplType:"question"},events:am,agentId:a,param:{entity_info:{},add_info:{ori_question:d},event_list:am,client_ip:a,question:d,user_id:r,user_name:a,trace_id:e,session_id:e,source:l,input_type:R}}],userId:r,userName:a,startTime:S,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:m,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:i,traceTableData:m,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fwhy-did-kzr-miss-earnings-forecasts-in-q3-9109c0\u002F",config:{_app:{basePath:an,assetsPath:an,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"Why did KZR miss earnings forecasts in Q3?","a5d0551a-ec43-404e-b317-c6fb5d4d7da1","progress\u002Fsearching_for",1000,"searching_for",0,"other\u002FopenAnswer","llm_generated","ths_ainvest_lite_web",null,"📊 How did KZR's revenue performance compare to analyst expectations in Q3?","〽️ What were the key factors that contributed to KZR's earnings miss in Q3?","🔍 What is the current market sentiment towards KZR's stock after the earnings announcement?","STR","dp56322314","thinking","The user wants to analyze why KZR missed earnings expectations in Q3. I should focus on actual earnings, earnings surprise, latest earnings report, analyst opinions, and factors contributing to the earnings miss. I will use FinQuery and Search for the related data and information.","auto","agent","411c586b32a2e8ad","explain news events","Searching Web","signal",2001,"rich_text","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","Kezar Life Sciences Inc. (KZR) did not miss earnings forecasts in Q3; in fact, the company's Q3 2024 earnings per share (EPS) estimates were actually increased by William Blair analyst M. Phipps, from ($0.34) to ($0.30). However, the company's financial results for Q3 2024 showed a reported EPS of ($0.30), which met the revised estimates set by William Blair. Therefore, Kezar Life Sciences did not miss the earnings forecasts in Q3 2024.",2,"Kezar Life Sciences, Inc. (NASDAQ:KZR) Forecasted to Post Q3 2024 Earnings of ($0.30) Per Share","Get Kezar Life Sciences alerts: Kezar Life Sciences, Inc. (NASDAQ:KZR – Free Report) – Investment analysts at William Blair boosted their Q3 2024 earnings per share (EPS) estimates for shares of Kezar Life Sciences in a research report issued on Tuesday, August 13th. William Blair analyst M. Phipps ...","https:\u002F\u002Fwww.americanbankingnews.com\u002F2024\u002F08\u002F17\u002Fkezar-life-sciences-inc-nasdaqkzr-forecasted-to-post-q3-2024-earnings-of-0-30-per-share.html","2024-08-16","411c586b32a2e8ad_0","oeqxkhszf","oeqxkhszf_layer","base","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite",1744361037276,"stock","186",999,"Kezar Life Sciences Inc. (KZR) did not miss earnings forecasts in Q3; in fact, the company's Q3 2024 earnings per share (EPS) estimates were actually increased by William Blair analyst M. Phipps, from ($0.34) to ($0.30)[^2]",". However, the company's financial results for Q3 2024 showed a reported EPS of ($0.30), which met the revised estimates set by William Blair[^2]. Therefore, Kezar Life Sciences did not miss the earnings forecasts in Q3 2024.","Kezar Life Sciences","2+679_496_21_554+0+0+a5d0551a-ec43-404e-b317-c6fb5d4d7da1+a35b69aada09e4776807e093159a2380+llm_generated+aimeTagAnalysis+0+0.07476364076137543+1","2+679_496_21_554+0+0+a5d0551a-ec43-404e-b317-c6fb5d4d7da1+59c34657ae695a0fa7de1a68f901c973+llm_generated+aimeTagAnalysis+0+0.05004969611763954+2","2+679_496_21_554+0+0+a5d0551a-ec43-404e-b317-c6fb5d4d7da1+f4d6862cdd745ed46bc82151d98110bf+llm_generated+aimeTagAnalysis+0+0.04945509508252144+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","aigc",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>